IBT-T03H
Phase 1- Indications
- Marburg virus disease
Company intelligence / Profile preview
IBT Bioservices provides comprehensive in vitro and in vivo contract research services with expertise in infectious diseases. The company supports vaccine and therapeutic development for both small biotech firms and large pharma clients. It has contributed to the development of monoclonal antibodies against Marburg virus disease, supported COVID‑19 product development through pseudovirus production/assays, and offers BSL‑2 testing with access to BSL‑3/4 via partners. Its parent company has received NIH/NIAID funding for anti-filovirus programs.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on IBT Bioservices.